Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
暂无分享，去创建一个
M. Stauch | A. Hinke | W. Brugger | N. Niederle | F. Kauff | U. Kaiser | M. Welslau | M. Rummel | M. Sandherr | L. Mueller | E. Weidmann | C. Losem | W. Blau | J. Barth | L. Hahn | C. Balser | Ulrich von Gruenhagen | H. Boeck | Julia Vereshchagina